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Hyperphosphataemia is one of the most common and challenging conditions in 
haemodialysis (HD) patients, affecting between ~50% and 80% of the patient 
population. The condition is accompanied by severe complications and premature 
death. Main interventions in the management of hyperphosphataemia include dietary 
phosphate restrictions, phosphate-binding agents and dialysis removal. However, the 
high prevalence of hyperphosphataemia indicates that these approaches are deficient. 
Current practise is challenged in various ways, for example by the risk of protein 
malnutrition following dietary restrictions, an insufficient effect of the phosphate-
binding agents and ineffective dialytic removal of phosphate due to, for instance, lack 
of individualised dialysis prescriptions.  
Physiological modelling in the form of phosphate kinetic modelling may further our 
understanding of phosphate kinetics in HD patients. Furthermore, it can help quantify 
dialytic phosphate removal and has the potential to help individualise current or new 
treatment regimens and generate new inputs to the teaching part - overall with a view 
to improving hyperphosphataemia management. This PhD study evaluates current 
phosphate kinetic modelling approaches in chronic HD therapy and presents new 
perspectives. The aim is to improve our insight into intra- and post-dialytic phosphate 
kinetics and to provide novel modelling tools that can aid current practice in 
hyperphosphataemia management, including perhaps in the handling of dialysis 
prescribing. 
The thesis consists of four studies. The first study is a model study presenting the 
development and evaluation of a new phosphate kinetic model on average plasma 
phosphate samples. The model includes a predictive model of intra-dialytic (four- and 
eight-hour) and post-dialytic (two-hour) values of plasma phosphate in HD therapy. 
Distribution volume assessment was part of the modelling process. The second study 
is a systematic review of phosphate kinetic models in HD therapy. The review 
provides insight into and in-depth comparison of existing models. The review is 
followed by another model study. Hence, the third study includes modifications and 
validation of the most promising model variation of the first study, a three-
compartment model. The study aims at individualising the model and validating the 
model on individual patient data with a view to assessing the precision and the 
temporal robustness of the model predictions. Furthermore, adjustments are made to 
make the model more consistent with physiological expectations. The fourth and final 
study is an addition to the model presented in the third study. The focus of this study 
is to evaluate and validate the addition of an assumed intra-dialytic coagulation 
component to the model by adding a linear clearance reduction (/h) to the transport 
component of phosphate between dialysate and plasma. 
The results of the thesis indicate that the modelling approaches (Study I, III and IV) 
seem promising in simulating phosphate kinetics in individual chronic HD patients; 
especially intra-dialytic phosphate kinetics. The temporal robustness of the model 
predictions is also cautiously concluded on the basis of Study III. Furthermore, the 
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idea of adding a coagulation component to the model to simulate intra-dialytic 
coagulation could provide a promising input to current phosphate kinetic modelling, 
for instance as a potentially useful tool for detection of clotting problems. Thus, the 
perspectives and ideas emanating from this PhD study may inform existing knowledge 
and contribute to devising clinically useful solutions. However, even though 
promising, the model with and without the coagulation component need further 
validation, especially with a focus on post-dialytic kinetics. In this regard, it would be 
highly relevant to test the model on a larger sample and it could be relevant to consider 
implementing (and validating) other model components that might influence the intra- 



















Hyperfosfatæmi er en af de mest almindelige og mest udfordrende tilstande hos 
hæmodialysepatienter (HD-patienter). Tilstanden rammer mellem 50% og 80% af 
patienterne og er forbundet med alvorlige komplikationer og tidlig død. De 
overordnede interventioner i håndteringen af hyperfosfatæmi består af 
diætbegrænsninger, fosfatbindere og dialysefjernelse. Den høje forekomst af 
hyperfosfatæmi tyder imidlertid på, at disse tilgange er utilstrækkelige. Der findes 
forskellige udfordringer i den nuværende praksis, herunder risiko for proteinrelateret 
fejlernæring ved overholdelse af diætbegrænsningerne, utilstrækkelig virkning af 
fosfatbindere og ineffektiv dialyse bl.a. pga. utilstrækkelig individualisering af 
dialyseordinationerne. 
Fysiologisk modellering i form af fosfatkinetisk modellering er en lovende tilgang til 
en dybdegående forståelse af fosfatkinetik hos HD-patienter. Desuden kan metoden 
understøtte beregningerne af den dialytiske fosfatfjernelse samt potentielt understøtte 
individualisering af nuværende og nye behandlingsregimer samt frembringe nye 
input til undervisningsdelen - samlet set med henblik på at forbedre håndteringen af 
hyperfosfatæmi. Dette ph.d.-studie evaluerer aktuelle fosfatkinetiske modeller inden 
for kronisk HD behandling og præsenterer nye perspektiver på området. Fokus er at 
højne vores indsigt i forhold til intra- og postdialytisk fosfatkinetik og at levere nye 
og forbedrede modelleringsværktøjer, der kan understøtte den nuværende praksis i 
håndteringen af hyperfosfatæmi herunder måske i dialyseordinationer.   
Afhandlingen består af fire studier. Det første studie er et modelstudie, der 
præsenterer udformningen og evalueringen af en ny fosfatkinetisk model med afsæt 
i gennemsnitlige plasmafosfatprøver. Modellen indbefatter en prædiktiv model af 
intradialytiske (fire og otte timer) og postdialytiske (to timer) plasmafosfatværdier 
inden for HD behandling. Det andet studie er et systematisk review af fosfatkinetiske 
modeller inden for HD, som giver indsigt i og en grundig sammenligning af 
eksisterende modeller. Reviewet efterfølges af endnu et modelstudie. Det tredje 
studie omfatter således modifikationer og validering af den mest lovende 
modelvariation, en trekompartmentmodel, fra det første studie. Dette studie har til 
formål at individualisere modellen og validere den på individuelle patientdata med 
henblik på at vurdere præcisionen og den tidsmæssige robusthed af 
modelprædiktionerne. Formålet er endvidere at justere modellen til at være i bedre 
overensstemmelse med de fysiologiske forventninger. Det fjerde og sidste studie er 
en tilføjelse til modellen fra studie tre. Fokus for dette studie er at evaluere tilføjelsen 
af en intradialytisk koagulationskomponent (kredsløbs- og filterkoagulation) til 
modellen ved at tilføje det som en lineær clearance-reduktion (/time) til 
transportkomponenten af fosfat mellem dialysatet og plasma. 
Resultaterne af ph.d.-studiet indikerer, at modelleringen (Studie I, III og IV) er 
lovende i forhold til at simulere fosfatkinetik hos individuelle kroniske HD-patienter 
især intradialytisk fosfatkinetik. Det kan også med baggrund i Studie III med 
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forsigtighed udledes, at modelprædiktionerne har en tidsmæssig robusthed. Desuden 
kan forslaget om at tilføje en koagulationskomponent til modellen med henblik på at 
simulere intradialytisk koagulation være et lovende input til den nuværende 
fosfatkinetiske modellering, fx som et potentielt brugbart værktøj til at detektere 
klotningsproblemer.  Perspektiver og ideer fra dette ph.d.-studie kan således muligvis 
præge den eksisterende viden og dermed måske bidrage til at udvikle nye klinisk 
nyttige løsninger. Men trods de lovende resultater er der behov for yderligere 
validering af modellen både med og uden koagulationskomponenten, især med fokus 
på postdialytisk kinetik. I den forbindelse ville det være yderst relevant at teste 
modellen på en større population, og det kunne være relevant at overveje at 
implementere (og validere) andre modelkomponenter med potentiel indflydelse på 
den intra- og postdialytiske plasmafosfatkoncentration.
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PREFACE  
The idea for this thesis originates partly from my work as a dialysis nurse in clinical 
practice and partly from my final semester at the Master’s education in Clinical 
Science and Technology at Aalborg University. In our Master’s thesis, my co-student 
Amanda Buus and I started working with the subject of phosphate modelling in 
haemodialysis (HD) and obtained promising results. This work inspired me to 
continue research within the field.  
One goal of the present PhD was to survey and compare existing phosphate kinetic 
modelling approaches in the field of chronic HD therapy. Another goal was to present 
and evaluate new model solutions in the field in order to devise useful tools for 
management of hyperphosphataemia in HD patients. Thus, the thesis presents no final 
solution but offers novel perspectives and ideas that may inform existing knowledge 
and hence contribute to devising clinically useful solutions. 
The thesis was conducted at the Department of Health Science and Technology at 
Aalborg University, Denmark, from November 2013 to August 2020, with financial 
support from the Doctoral School in Medicine, Biomedical Science and Technology, 
Aalborg University, and the Danish Diabetes Academy supported by the Novo 
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CHAPTER 1. INTRODUCTION 
Hyperphosphataemia, i.e. plasma phosphate >1.4 mmol/L (8), is one of the most 
frequently observed electrolyte disturbances in haemodialysis (HD) patients. This 
disturbance affects between ~50% and 80% of dialysis patients (9–11). It is 
associated with serious adverse outcomes and imposes a significant burden on both 
patients and healthcare resources. As a result, hyperphosphataemia is widely 
recognized as one of the most important clinical targets in the treatment of HD 
patients (8,9,12,13). 
The main interventions in hyperphosphataemia management in HD patients include 
dietary restrictions, phosphate-binding agents and dialysis removal (13–15). 
However, the high frequency of hyperphosphataemia indicates that these 
interventions have largely failed and that improvements are needed.  
Physiological modelling, in the form of kinetic modelling, can provide an important 
tool to increase our understanding about the physiological processes and problems 
when evaluating phosphate kinetics in HD patients (2,16,17). Hence, a model 
compatible with phosphate kinetics in HD therapy could be beneficial for improving 
current treatment regimens.  
The potential benefits of physiological modelling are the main focus of this thesis. 
More precisely, the thesis focuses on intra- and post-dialytic phosphate kinetic 
modelling in chronic HD therapy. The end of goal is to clarify existing modelling 
approaches and to add new and useful model suggestions to the area of interest.  
The thesis is based on four studies. The first study (1) (Study I) includes a description 
of the development and validation of a new phosphate kinetic model in HD therapy 
based on distribution volume assessment; a seemingly overlooked approach. The first 
study is followed by a systematic review (2) (Study II) of phosphate kinetic models 
in HD therapy. This study aims to identify and provide in-depth insight into existing 
phosphate models. The third study (Study III) is an addition to Study I. This study 
aims at improving the best performing model presented in the first study by fitting it 
to individual patient data aiming at making it more compatible with individual 
phosphate kinetics and physiological expectations. Furthermore, the study aims to test 
the temporal robustness of model predictions. Finally, the focus of the fourth study 
(6) (Study IV) is to add intra-dialytic circuit and dialyzer coagulation as a component 









CHAPTER 2. BACKGROUND 
This chapter introduces the background for the thesis. It gives a general introduction 
to hyperphosphataemia in relation to HD. The chapter also describes current 
interventions in hyperphosphataemia management and offers perspectives on current 
challenges. This leads to a section that presents the method of physiological 
modelling, model validation considerations and current challenges in phosphate 
kinetic modelling in relation to HD therapy.  
2.1. HYPERPHOSPHATAEMIA IN HAEMODIALYSIS PATIENTS 
The number of people undergoing dialysis continues to increase worldwide. For 
instance, due to the improved treatment regimens for diabetes and hypertension, the 
prevalence of dialysis patients is expected to double from approximately 2.62 million 
worldwide (in 2010) by 2030 (18,19) (14,15). HD therapy is the most common type 
of dialysis accounting for approximately 89% of dialysis patients (20). Dialysis (or a 
kidney transplant) becomes necessary when the kidneys fail to uphold vital functions, 
i.e. when the patient is at the stage of kidney failure. According to international 
guidelines, the Kidney Disease Improving Global Outcomes (KDIGO), kidney failure 
is defined as a glomerular filtration rate (GFR) below 15 ml/min/1.73m2 (14) (Table 
1). The GFR, a marker of the stage of kidney disease, denotes the filtration capacity 
of the kidneys, i.e. the rate at which the glomeruli filter wastes and fluid from the 





     Table 1. The KDIGO stages of kidney disease (14). GFR: glomerular filtration rate. 
Kidney failure is associated with various abnormalities and disorders (14). 
Hyperphosphataemia is one of the most frequently observed disorders in HD patients 
caused mainly by the reduced excretion resulting from the impaired renal function 
(14,15,22,23). The disorder affects approximately 50-80% of the HD population (9–
11).  
The following subsections give an account of aspects relevant when considering 
hyperphosphataemia in HD patients.
Stage Specification GFR    
(ml/min/1.73 𝐦𝟐) 
G1 Normal or high  ≥ 90 
G2 Mild decrease 60-89 
G3a Mild to moderate decrease 45-59 
G3b Moderate to severe decrease 30-44 
G4 Severe decrease 15-29 
G5 Kidney failure  < 15 




Phosphorus is a mineral widely present in the human body as inorganic phosphate 
(PO3−4). Inorganic phosphate plays an essential role in physiological processes, for 
instance, bone metabolism, energy metabolism, cellular signalling and glycolysis. 
Hence, it is most commonly found in phospholipids, nucleotides, deoxyribonucleic 
acid (DNA), ribonucleic acid (RNA) and in forms of adenosine phosphates: 
monophosphates (AMP), diphosphates (ADP) and triphosphates (ATP) (13,24–26). 
The total phosphate content in the adult body is approximately 700 g. About 80%–
85% is found in the skeleton as the structural material of bone and teeth where 
phosphate acts as a buffer to maintain a relatively stable phosphate balance. The 
remaining 15%–20% is present in body fluids and soft tissues. The extracellular space 
accounts for 1% of the total body phosphate, mainly as organic phosphate contained 
in phospholipids. Hence, the amount of phosphate measurable in clinical practice 
represents <1% of total body phosphate (13,24–26).  
Figure 1 provides a simplified overview of the most important physiological 
mechanisms involved in phosphate regulation in the human body. 
                 
Figure 1. Regulation mechanisms of phosphate in the human body. 
 




2.1.2. BONE AND MINERAL METABOLISM 
An introduction to bone and mineral metabolism is a prerequisite to understanding the 
pathology of hyperphosphataemia and the phosphate balance. This section presents 
some of the most important elements of the metabolic processes. 
Bone and mineral metabolism is a closely regulated process essential for normal 
growth and a functioning organism. The process is influenced by a number of 
hormones that establish the phosphate and calcium balance. Some of the most 
important hormones include calcitriol (active vitamin D), calcitonin and parathyroid 
hormone (PTH). Calcitonin is secreted from the parathyroid glands, whereas PTH is 
secreted from the thyroid gland. These hormones primarily act on three organs: 
kidneys, bones and intestines (26–28). 
Phosphate (in the form of phosphorus) and calcium are absorbed through passive and 
active intestinal processes. The active processes are stimulated by calcitriol which 
increases intestinal absorption. Calcitriol also contributes to absorption of calcium and 
renal phosphate secretion. Moreover, calcitriol stimulates the bone calcification 
processes and the activity of the bone-regulating cells; osteoclasts and osteoblasts 
(26,27).  
PTH has considerable influence on the metabolic processes, all of which serve to 
regulate blood calcium. Thus, PTH stimulates calcium release and skeletal phosphate 
resorption, increases renal and intestinal calcium absorption, increases urinary 
excretion of phosphate and promotes renal conversion of vitamin D to calcitriol. PTH 
secretion diminishes when there is too much calcium in the blood (negative feedback) 
but increases in response to low serum calcium or high serum phosphate (positive 
feedback). Calcitonin helps remove calcium from the blood at high serum 
concentrations (positive feedback) by inserting it into the bones and by increasing 
renal excretion (26–28). 
Table 2 outlines the involvement of organs and hormones in bone and mineral 
metabolism. The metabolic processes are also influenced by the hormone fibroblast 
growth factor-23 (FGF-23), the main function of which seems to be regulation of 
plasma phosphate. The hormone is secreted by osteocytes and osteoblasts in response 
to elevated plasma phosphate and calcitriol and decreases renal phosphate 
reabsorption and increases urinary excretion. FGF-23 may also suppress the enzyme 
1-alpha-hydroxylase reduce and thereby reduce vitamin D activation (26,29–33).  
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Table 2. Overview of the hormonal involvement in bone and mineral metabolism. PTH: 
Parathyroid hormone. 
2.1.3. HYPERPHOSPHATAEMIA-RELATED CONSEQUENCES 
Declining kidney function will eventually lead to disturbances in bone and mineral 
homeostasis. These disturbances include 1) altered blood levels of phosphate, 
calcium, PTH and calcitriol, 2) extra-skeletal calcifications and 3) disturbances in 
bone modelling or remodelling (26,34). 
Hyperphosphataemia is observed when GFR reaches approximately 20-35 
ml/min/1.73 m2 (see Table 1) (14,21,26). The disturbance accelerates the progression 
of kidney disease and results in changes in bone and mineral metabolism, which has 
different physiological consequences (14,15,32,34,35). The changes and some of the 
related consequences of hyperphosphataemia are outlined in Figure 2. 





Figure 2. Changes relating to hyperphosphataemia and some of the related consequences. 
PTH: Parathyroid hormone; FGF-23: Fibroblast growth factor-23. 
Hyperphosphataemia is known to accelerate vascular calcifications processes. This is 
mainly due to an increase in the calcium-phosphate product (see Figure 2) as a result 
of the direct increase in phosphate and the reduced mobilisation of minerals in bones. 
If the calcium-phosphate product is too high, it crystallises and is deposited within the 
vasculatures and soft tissues (26,34,36). Hence, it is recommended that the calcium-
phosphate product does not exceed 55 mg2/dL2 (37). Vascular calcifications occur 
even in younger patients and are common in HD patients. For instance, coronary 
artery calcifications are observed in 70-80% of HD patients (26).  
Vascular calcifications are highly associated with cardiovascular events 
(12,26,38,39). The risk of cardiovascular events increases exponentially with 
decreasing kidney function; a process that begins already when the kidney function is 
reduced by one third (39).  
Cardiovascular complications increase the risk of death even in younger HD patients 
and contribute to approximately 50% of all deaths among HD patients (40,41). For 
instance, the risk of cardiovascular mortality is approximately 10-30 times higher in 
HD patients than in the general population (42,43). The correlation between an 
increase in plasma phosphate and premature death in chronic kidney disease (CKD) 
patients was presented in 2011 in an extensive systematic review and meta-analysis. 
The review found that the overall risk of death rose by 18% for each 0.3299 mmol/l 
increase in plasma phosphate (44). 




Secondary and tertiary hyperparathyroidism are other consequences of 
hyperphosphataemia that cause excessive PTH secretion. As illustrated in Figure 2, it 
is evident that hyperparathyroidism can be a result of the direct or indirect influence 
of high plasma phosphate levels. An indirect mechanism includes a decrease in serum-
free calcium as hypocalcaemia stimulates PTH secretion. Moreover, 
hyperphosphataemia leads to hyperparathyroidism because of decreased renal 
calcitriol production, either directly or indirectly by increasing FGF-23 levels. 
Symptoms of hyperparathyroidism include bone and joint pain, fragile bones, limb 
deformities, kidney stones, excessive urination, abdominal pain, nausea, vomiting, 
loss of appetite, weakness, fatigue, depression, forgetfulness and immune system 
effects (21,45,46). 
Another consequence of hyperphosphataemia that affects most HD patients is renal 
osteodystrophy (47). Renal osteodystrophy is a bone disease occurring when the 
kidneys fail to sustain proper blood levels of phosphate and calcium. As illustrated in 
Figure 2, this may be due to an increase in PTH or a decrease in renal calcitriol 
production. Renal osteodystrophy includes a number of underlying bone diseases such 
as osteoporosis, adynamic bone disorder, osteomalacia and osteitis fibrosa (see Figure 
2). The condition contributes to bone fractures, bone pain, myopathy, muscle pain, 
tendon ruptures and periarthritis. For instance, the incidence of hip fracture has been 
found to be more than five times higher in HD patients than in the average population 
(48).  
The severe consequences of hyperphosphataemia impose a significant burden on both 
patients and healthcare resources. Therefore, control of this marker is crucial.  
2.2. MANAGEMENT OF HYPERPHOSPHATAEMIA   
The overall aim of hyperphosphataemia management in HD patients is to maintain 
plasma phosphate at a near-normal range of 0.9–1.4 mmol/l (8,9). 
Hyperphosphataemia prevention and treatment include a combination of dietary 
phosphate restrictions, administration of phosphate-binding agents to reduce intestinal 
phosphorus absorption, calcitriol supplementation and adequate dialysis removal 
(14,15). Hyperphosphataemia treatment is relevant when GFR reaches approximately 
20-35 ml/min/1.73 m2 (14,21). At this point, dietary modifications and phosphate-
binding agents are usually enough to achieve phosphate levels within the normal 
range. In the end-stage of the disease (GFR< 10 ml/min/1.73 m2), dialysis (or 
transplantation) becomes necessary to maintain a normal phosphate balance (14).  
This section presents the monitoring guidelines and procedures for managing 
hyperphosphataemia in HD and elaborates on the three main interventions: dietary 
restrictions, treatment with phosphate-binding agents and dialysis. The final section 
in this part addresses challenges encountered in current practice.  




2.2.1. MONITORING HYPERHOSPHATAEMIA  
Regular blood samples are obtained according to international guidelines (15) to 
detect abnormal plasma phosphate values and support regulation of phosphate through 
dietary measures and doctor's prescriptions. The frequency of blood phosphate 
sampling in HD is typically once a month, but the monitoring interval is between one 
and three months. 
Blood sampling results support the patient's diet and phosphate binder intake and 
healthcare professionals’ recommendations and doctor’s prescriptions (15).  
2.2.2. DIETARY RESTRICTIONS AND PHOSPHATE-BINDING AGENTS 
A phosphorus-lowering diet, i.e. food items low in phosphate, is the first step in 
preventing and managing reduced phosphate secretion. This includes a recommended 
phosphorus intake of 800-1000 mg/day (14,15). The average phosphorus intake in 
healthy adults is approximately 1000-1400 mg/day (26). The dietary restrictions 
include reduced intake of dairy products, meats, fish, whole grain products and other 
food items high in phosphorus. Moreover, home-made meals are recommended 
because of a high phosphorus content in various food additives (26,49,50). Normally, 
the intestinal absorption of phosphorus is about 60-70% (26). However, the intestinal 
absorption of phosphorus is about 80% in patients treated with calcitriol (13,51). 
Calcitriol accounts for most of the uptake in HD patients as the ability to activate 
vitamin D is reduced when kidney function declines (14,15).  
Usually, dietary restriction is supplemented with phosphate-binding agents when 
GFR<25-35 ml/min/1.73m2 (see Table 1)(14,15). Hence, at this point, up to 88% of 
CKD patients already need phosphate-binding agents to ensure a normal phosphate 
balance (52). Phosphate-binding agents reduce gastrointestinal absorption of 
phosphorus when it is consumed before, during or immediately after a meal. They 
reduce the absorption by forming poorly soluble compounds with phosphorus in the 
intestinal tract and by ensuring excretion of phosphorus (53).  
 
2.2.3. HAEMODIALYSIS 
HD is a procedure that substitutes many of the normal kidney functions by removing 
excess water, solutes and toxins from the blood using a special dialysis solution, 
dialysate. In HD, blood is circulating in a closed extracorporeal system and through an 
external filter (a dialyzer) that contains a semipermeable membrane that helps remove 
waste and water mainly by diffusion to the dialysate. The blood is accessed using either 
an arteriovenous (AV) fistula, a central venous catheter or an AV graft (54,55). Other 
treatment modalities include some HD subtypes; haemofiltration (HF) and 
haemodiafiltration (HDF). HF is a convective technique that does not include 
dialysate. Instead, it uses a large amount of ultrafiltration to remove the waste 
products. The removed fluid is exchanged with sterile replacement fluid. HDF is a 
treatment modality where HD and HF are performed simultaneously (54,55). Table 3 
shows some examples of the ranges of phosphate removal by different treatment 
modalities (13). 




Treatment Grams per week 
CHD, 4 hours 2.3-2.6 
Extended HD, ≥ 5 hours 3.0-3.6 
NHD, ~ 8 hours 4.5-4.9 
Table 3. Ranges of phosphate removal by different dialysis modalities (13). CHD: Conventional 
haemodialysis; NHD: Nocturnal haemodialysis. 
2.2.4. CHALLENGES IN CURRENT PRACTICE 
Normalisation of plasma phosphate is difficult to obtain in HD patients (56). One 
challenge is non-adherence to the recommended dietary restrictions (56,57). An 
extensive systematic review of dietary adherence in end-stage kidney disease (72% 
HD studies) reports non-adherence in 43.5–84.5% of patients (58). This is supported 
by another study reporting that 75-85% of HD patients do not adhere to overall CKD 
dietary restrictions that include sodium, phosphorus, potassium and fluid intake (57). 
Moreover, it is estimated that food additives account for 10–50% of total phosphorus 
intake per day, an aspect which complicates adherence to dietary recommendations 
(49). As phosphorus is naturally found in protein-rich foods such as dairy products, 
meat and fish, adherence to dietary restrictions is further complicated by the risk of 
protein malnutrition. This problem needs to be addressed as protein malnutrition is 
associated with an increased risk of morbidity and mortality (59). Dialysis patients are 
at particular risk of protein malnutrition due to, for instance, loss of appetite, chronic 
inflammation and dialysis-associated amino acid and protein loss. Thus, it is estimated 
that approximately 20-50% of dialysis patients suffer from protein malnutrition (59). 
Because of the high risk of malnutrition in particular, dietary phosphate restriction is 
not sufficient to control plasma phosphate levels (13). 
Another challenge in the management of hyperphosphataemia includes insufficient 
phosphate binder intake. Hence, most patients receiving phosphate-binding agents do 
not achieve target phosphate levels (60). A systematic review from 2015 of 44 studies 
on medication adherence in HD patients found that 13-99% (median 53%) did not 
adhere to phosphate binder regimens (61). One reported issue is non-adherence due 
to forgetfulness, indifference, lack of understanding, total pill burden and depressive 
symptoms (61–63). Another issue is the prescription of a standard phosphate binder 
regimen, typically 2-3 tablets three times a day, which does not allow for variations 
in meal content. This introduces a problem as phosphate intake typically varies 
between 100 and 800 mg during the day. Hence, studies indicate that only 30% of 
meals include an adequate phosphate binder dosage (24,64). In addition, snacks tend 
to be ignored even though snacks are found to contribute to up to 400 mg of the total 
daily phosphate intake (64). A third issue relating to phosphate-binding agents 
includes various side effects such as gastrointestinal disturbances, aluminium toxicity 
and calcium overload (24,65). Finally, phosphate binder prescriptions are restricted 
due to economic considerations (62). 
Dialysis treatment is also associated with different challenges in the management of 
hyperphosphataemia. One challenge is that phosphate tends to bind firmly to water 




particles in the blood which hinders diffusion of phosphate to the dialysate (66). 
Moreover, there seems to be an intra- and inter-dialytic inflow of phosphate into 
plasma from other body compartments. For instance, it is well-studied that the blood 
phosphate level drops rapidly during the 2 hours of conventional 4-hour HD (CHD) 
treatment and then stabilise. This is followed by a rebound of plasma phosphate 
beginning either at the end of treatment or after dialysis is terminated (51,67–69). 
However, in spite of these known challenges, dialysis treatment is known to contribute 
to a better phosphate balance by increasing the dialysis frequency or duration 
(13,15,70). For instance, a systematic review of extended nocturnal HD (NHD) 
compared with CHD showed a decrease in serum phosphate levels of 0.97 mg/dL in 
an 8-hour NHD dialysis session compared with a 4-hour CHD treatment (71). 
However, convincing patients to stay longer on dialysis may be difficult if they are 
not undergoing treatment at home as they already spend many hours in the dialysis 
ward. Another problem is that many patients miss treatments or shorten the treatment 
time. For instance, a review on phosphate-control adherence has reported that 32% of 
HD patients shorten their treatment time, whereas up to 35% miss treatments 
occasionally (56). 
It should also be emphasised that different dialysis parameters such as dialyzer as well 
as blood and dialysate flow rates may influence dialytic phosphate removal. 
Moreover, it has been found that phosphate clearance decreases with increasing 
haematocrit and coagulation of the extracorporeal system and dialyzer (69,72,73).   
Another relevant challenge that needs to be addressed is an observed lack of insight 
among HD patients into key aspects of their treatment and disease. Different studies 
point out that this may be related to insufficient information (74,75). An important 
area where there appears to be inadequate information is within diet and medicine 
(59,76–78). This poses a significant problem, as sufficient information on dietary 
regimes and related drug intake appears to be a key need among patients (78). It is 
apparent in this context that sufficient information and guidance have a positive effect 
on the individual's independence and adherence to treatment recommendations. 
Insufficient information and lack of insight may thus lead to an increased risk of 
disempowering the patient and unsatisfactory compliance with dietary and phosphate 
binder restrictions (78,79).  
2.3. PHOSPHATE KINETIC MODELLING IN HAEMODIALYSIS 
The high frequency of hyperphosphataemia in HD patients indicates that current 
practice is insufficient and deserves attention (9,10). To make changes to current 
practise, it is important to have an in-depth understanding about the phosphate kinetics 
of the population of concern. Physiological modelling in the form of kinetic modelling 
is widely used and can provide new insights furthering our understanding and 
handling of biological processes, for instance by investigating new dialysis methods 
(16,80). Other practical applications could take the form of model-based decision 
support. Hence, model-based decision support could perhaps help individualize 
current HD treatment regimens and work as an integrated decision support tool, for 
instance as part of dialysis adjustments, or it could serve educational purposes with a 




view to improving hyperphosphataemia management. Altogether, practical 
approaches would have to be working well, and a phosphate kinetic model would have 
to be accurate to ensure that the tool is reliable (16,17,80).  
This section presents the methods of physiological modelling and model validation 
and sheds light on current challenges related to phosphate kinetic modelling in HD 
therapy.  
2.3.1. PHYSIOLOGICAL MODELLING 
Physiological modelling is a representation of physiological reality expressed in the 
form of mathematical equations. The modelling approach aims to characterise the 
interactions of physiological subsystems, including various processes such as 
absorption, distribution and elimination in the body. These subsystems include one or 
more interconnected body compartments consisting of organs, body fluids and/or 
tissue spaces, etc. Moreover, the modelling approach considers observed 
physiological variables such as flow rates of circulating body fluids, body 
composition and the function of involved organs and plasma. Physiological modelling 
is a useful approach in various applications in biomedical engineering and medicine, 
especially in drug research and development (16,17). It is also applied within HD in 
the form of urea and creatinine modelling to predict the effect of dialysis techniques 
and procedures and to analyse the course of treatment, etc. Hence, physiological 
modelling can help the physician tailor treatment to the individual patient 
(16,54,81,82).  
The simplest physiological model is one that comprises a single compartment. This is 
often referred to as a one-compartment model that is normally set equal to the systemic 
blood circulation because it can be measured. The compartment includes a set of 
model equations for the mass, concentration and distribution volume for the given 
drug or substance of interest. Model equations are influenced by a number of 
parameters or variables, inputs, and generate some estimates or predictions of 
physiological variables - referred to as outputs (16,17). This specific model approach 









Figure 3. Example of one-compartment model equal to systematic blood circulation.  
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categories; predictive, descriptive, interpretive or explanatory. Predictive models can 
help determine how a system would react to changes or stimuli and thereby forecast 
future outcomes; for instance, they could be used to simulate how plasma phosphate 
would respond to dialysis treatment or dietary intake. Descriptive models are applied 
to describe quantitative relationships or systems accurately and briefly by 
mathematical expressions; for instance, they could describe a linear equation of two 
proportional variables. This approach would be simpler than a verbal or graphical 
description. The interpretive models are typically used to interpret experimental 
results; for instance, an interpretive model of renal function could include simulations 
of creatinine, and urea could be applied to forecast a recommended time for the next 
HD treatment for the individual patient. Finally, explanatory models can help explain 
some physiological changes, processes and effects in a system. Moreover, 
physiological models can be applied to estimate different parameters that are difficult 
to determine based on the available variables like input, for instance by using 
explanatory models (16,17).  
2.3.2. MODEL VALIDATION  
Thorough model validation and uncertainty assessment on the basis of experimental 
data are critical to ensure reliable model results. This should be an ongoing activity 
both during the development phase and once the model is complete. If the model is 
assessed to be in good agreement with the experimental data, it could be used as a tool 
for gaining insight into biological systems and to identify gaps in knowledge about 
the systems. If it is a predictive model, it could enable prediction of the future course 
of the biological system or variable (16,17). Hence, developing a reliable phosphate 
kinetic model could be an ideal approach for increasing our understanding of the 
complexity of phosphate kinetics in HD patients. A good predictive phosphate model 
could also forecast the course of plasma phosphate in different dialysis regimens and 
with the use of different parameters and thereby inform appropriate dialysis 
prescriptions tailored to the individual patient.  
A valid model is a model that successfully passes through the validation process. 
Thus, physiological modelling requires model validation as an ongoing process 
beginning when specifying the purpose of the modelling activity and ending when the 
model is complete. If new relevant theories and data become available, it could be 
necessary to make further adjustments to the model. Such modifications would 
involve further validation of the model (16,17).  
Cobelli et al. (2019) define model validation as follows: 
“Model validation involves assessing the extent to which a model 
is well-founded and tractable, while fulfilling the purpose for 
which it was formulated” (16).  
 
According to this definition, the validation approach first of all requires a clear and 
precise purpose. Hence, model validation involves evaluating the worth of the model 
to its intended purpose. If the purpose is not clearly stated, it will be impossible to 




make the necessary judgment as to whether the specific model is appropriate for its 
purpose or not (16). As implied in the definition, model validation is about evaluating 
whether the model is well-founded and tractable. To be well-founded, it is essential 
that the approach is thoroughly argued and that valid assumptions are made on the 
basis of relevant chemical and physical laws and principles that are being represented. 
To be tractable, the model has to be easily accessible and manageable in satisfying its 
intended purpose (16,17).   
According to Cobelli et al., the model will need to satisfy one or more of four criteria 
to be considered valid. The four criteria include theoretical, empirical, pragmatic and 
heuristic validity. The four validity criteria are outlined in Table 4.  
Validity criteria Assessment approach/focus 
Theoretical validity Is the assessment of the extent to which the model is 
compatible with accepted physiological theories → Is 
the model theoretically valid? 
Empirical validity Is the assessment of how well the model fits available 
empirical data → Is the model empirically valid?  
Pragmatic validity Is the assessment of the degree to which the predictive 
models support clinical decision making. The focus is 
to assess whether the model works with sufficient 
accuracy for the predictions to be clinically useful → 
Is the model pragmatically valid? 
Heuristic validity  Is the assessment of the extent to which the model can 
be used to test physiological hypotheses → Is the 
model heuristically valid? 
Table 4. The four validity criteria in model validation according to Cobelli et al. (16). 
Which of the four validity criteria would be relevant in the particular case is, of course,  
problem-specific and dependents on the intended purpose of the modelling activity 
(16). When the model’s validity is evaluated on the basis of experimental data, it is 
essential to consider the quality of these data. Thus, a successful outcome of the 
modeling activity will not only depend on the quality of the model. It will also 
critically dependent on the quality of the experimental data used to assess the model 
(16,17). High-quality experimental data require a rather controlled research process 
and setting to minimise bias, confounding, etc. Moreover, a suitable sample size is 
important to ensure an adequate data collection (83). Model validation on the basis of 
experimental data typically involves statistical and graphical comparisons; for 
instance, calculation of the coefficient of determination (R2) and the root-mean-square 
error (RMSE) (16,17).  
The validation process when comparing competing candidate models is another 
relevant perspective in the area of model validation. This process involves 
determining which of the models performs best in relation to the intended purpose; 
for instance, by comparison of RMSE or R2 values (16). 




2.3.3. CHALLENGES AND LIMITATION RELATED TO PHOSPHATE 
KINETIC MODELLING  
Phosphate kinetic models in HD therapy are available, but no model seems to have 
gained clinical acceptance, maybe because of the high complexity of phosphate 
kinetics which challenges the development and evaluation of phosphate kinetic 
models (54,81). Hence, even though various physiological and treatment-related 
components could influence the phosphate level (64,84–87), most existing models 
seem rather simple and incorporate only few model parameters. For instance, four 
identified models (88–91) only include between two and four relevant model 
components, e.g. dialyzer phosphate clearance and total distribution volume; and they 
ignore other known influencing parameters such as ultrafiltration rate, blood flow rate, 
coagulation of the dialyzer (and extracorporeal system) and haematocrit 
(64,72,73,84–87). Thus, one could question the theoretical validity of the models; and, 
indeed, if it is relevant at all to judge if the models have high empirical (and pragmatic) 
validity (16). Another perspective which also potentially hinders the development and 
evaluation of phosphate models is the lack of research into how phosphate models 
could be applied in practical settings. Hence, with no clear field of application, the 
motivation for and relevance of phosphate modelling presumably decreases. 
So far, mainly two-compartment models and pseudo-one compartment models, i.e. 
models with an accessible compartment plus an unknown contributor, have been 
proposed (88,89,92–94). However, these models are limited in different ways, for 
instance, due to unclear validation results, paediatric therapy and intra-dialytic HD 
exclusively. Hence, the potential for a new and improved model study seems obvious. 
In this regard, it could be relevant to investigate to which extent a multi-compartment 
model with more than two compartments could be beneficial in simulating phosphate 
kinetics in HD therapy. A four-compartment model was presented in 2002 by 
Spalding et al. (68) showing promising results. However, this model seems rather 
complex if it has to work in a clinical setting, and it only accounts for one hour post-
dialytic phosphate kinetics.  
Another unexplored area is to thoroughly compare existing phosphate kinetic models 
in HD therapy. The absence of such a comparison calls for a systematic review in this 
particular modelling field. A comprehensive survey and comparison of available 
phosphate models in terms of their applicability, contents and clinical feasibility 
would inform to the current debate about their potential and limitations, for example 
in relation to components, assumptions and clinical applicability. Hence, such a 
comparison could further clinicians and researchers’ insights and thus inspire further 
model development and validation.  
2.4. BACKGROUND SUMMARY 
Hyperphosphataemia is frequently observed in HD patients, and it is associated with 
serious adverse outcomes such as secondary and tertiary hyperparathyroidism, renal 
osteodystrophy, vascular calcifications and premature death. The phosphate balance 




is regulated by complex processes as part of the bone and mineral metabolism, which 
includes various hormones and organs.  
The main interventions in the management and prevention of hyperphosphataemia 
include dietary restrictions, phosphate-binding agents and dialysis removal (HD or 
PD). However, the high prevalence of hyperphosphataemia indicates that current 
interventions have failed substantially and that current practice needs improvements. 
There seems to be no simple and unambiguous answer to this problem. Dietary 
restrictions solve some of the problems, but the restrictions are not always respected 
due to, for instance, the risk of protein malnutrition. This problem also applies to 
conventional phosphate-binding agents which are neither consistently reliable nor 
sufficiently effective; and, moreover, they have a range of side effects. In comparison, 
prolonged dialysis could represent an effective solution. Hence, frequent and long-
term HD treatment is known to have a positive effect on the phosphate balance. 
However, dialysis phosphate kinetics are complex and not fully understood, and it is 
questionable if patients would choose an extended treatment regimen. 
Physiological modelling could be used for improving the management of 
hyperphosphataemia in HD patients. For instance, a duly functioning and validated 
model could help improve our understanding of the complexity of phosphate kinetics 
and thus potentially help individualise HD treatment to enhance dialytic phosphate 
removal. Furthermore, such a model could maybe also be used for educational 
purposes. However, no phosphate kinetic models have yet gained clinical acceptance. 
A particularly cumbersome issue in this context is the high complexity of phosphate 
kinetics, which challenges the development and evaluation of phosphate kinetic 
models. Moreover, it seems like existing models and modelling studies are limited in 
different ways. Examples are unclear validation results, paediatric focus, questionable 
practical use and insufficient post-dialytic considerations. Also, current models except 
for one include only up to two compartments. These aspects and limitations call for 
new model studies. A systematic review of existing phosphate models would also be 
highly relevant as no review includes a comparison and survey of existing phosphate 




CHAPTER 3. THESIS OBJECTIVES  
The previous chapters described how hyperphosphataemia is one of the most 
important and challenging clinical targets in the treatment of HD patients. If left 
untreated, hyperphosphataemia significantly increases the risk of morbidity and 
mortality. Hence, devising appropriate methods for managing and optimising HD 
patients’ phosphate balance is crucial, especially since no sustainable solution has yet 
been found with which to achieve stabilised phosphate levels in HD patients. Dialysis 
regulation and individualisation are possible solutions to obtain better phosphate 
control. Devising such solutions requires profound insight in and in-depth 
understanding of intra- and post-dialytic phosphate kinetics together with relevant 
decision support tools to assist optimal dialysis prescriptions. Phosphate kinetics 
modelling is seen as a potential tool in this regard and constitutes the focal point of 
this thesis. 
The overall research hypothesis of the thesis is that a three-compartment model can 
accurately simulate phosphate kinetics in haemodialysis.  
The overall objective of the thesis is two-fold;  
1) On the one hand, this thesis seeks to introduce novel model approaches as 
existing phosphate kinetic models in the field of HD seem to be inoperative 
or insufficient in different ways. Therefore, one objective is to present a 
novel model with the ability to simulate and predict intra- and post-
dialytic phosphate kinetics in HD patients. 
 
2) On the other hand, as a comprehensive survey and comparison of existing 
phosphate models is lacking, this thesis also seeks to gain in-depth insight 
into existing phosphate kinetics models. Therefore, another objective is to 
present a systematic review of current models. 
Papers I, III and IV aim to address the first objective, and Paper II aims to address the 
second objective. Table 5 provides an overview of the connection between the 
underlying objectives, papers and study approach(es). 
The thesis will exclusively focus on hyperphosphataemia management in chronic HD 
patients and it will not address hyperphosphataemia management related to other 
dialysis modalities or to the kidney transplant area.   
 
 




Study Title of paper Research objective(s) Study approach(es) 
I Distribution volume 
assessment using 
compartment modelling: 
phosphate kinetics in 
haemodialysis therapy 
(1) 
To develop and test a new 
predictive phosphate kinetic 
model in HD with the aim 
of using distribution volume 
assessment to determine 
distribution volumes values 
Compartment 
modelling and model 
validation on mean 
experimental data 
based on sampling 
from eight HD 
patients 
II Phosphate kinetic 
models in 
haemodialysis: A 
systematic review (2) 
To review the field of 
phosphate kinetic models to 
gain further insight into 
their potential and 
limitations 
Systematic review of 
existing phosphate 
kinetics models 
III Evaluation of a 
phosphate kinetic model 
in haemodialysis 
therapy –assessment of 
temporal robustness of 
model predictions 
 
To improve the best 
performance model from 
Study I by individualising 
the model, making it more 
compatible with 
physiological expectations 
and testing its temporal 
robustness 
Compartment 
modelling and model 
validation on 
individual samples 
from 12 HD patients 
collected during two 
separate treatments 
per patient  
IV Implementation of a 
coagulation component 
into a phosphate kinetic 
model in haemodialysis 
therapy – a potentially 
useful tool for quan-
titative detection of 
clotting problems 
To test if a phosphate 
kinetics model improves 
when a linear clearance 
reduction is added as an 
assumed intra-dialytic 
coagulation component  
Compartment 
modelling and model 
validation using the  
same patient data as 
Study III  
Table 5. Overview of the studies, papers, research aims and study approach(es). 
The following four chapters present some key aspects of each of the four studies that 




CHAPTER 4. STUDY I  
This chapter summarises the work conducted in the paper entitled “Distribution 
volume assessment using compartment modelling: phosphate kinetics in hemodialysis 
therapy” (1). The summary focuses on the methods, results and conclusions. 
4.1. METHODS 
The first study aimed to develop and test a new model approach of intra- and post-
dialytic (2 hours) phosphate kinetics in HD therapy. This section presents the model 
and evaluation approaches.  
4.1.1. PHOSPHATE KINETIC MODEL 
The model approach was used to simulate plasma phosphate during HD as a function 
of time and two hours after treatment. The goal was to achieve the best prediction of 
plasma phosphate using a simple model comprising predictive compartment 
modelling with one-, two-, and three-compartment simulations with 15 minutes in 
between simulations. Diffusive phosphate transport between compartments and a 
linear model structure were assumed in the two- and three-compartment simulations. 
Moreover, assumptions were made that three parameters, f1-f3, were the only 
parameters influencing plasma phosphate: f1 = phosphate eliminated through dialysis 
clearance at time t, f2 = diffused phosphate between compartments 1 and 2 at time t, 
and f3 = diffused phosphate between compartments 2 and 3 at time t. Figure 4 
illustrates the model structures and location of the three parameters f1-f3. The 
phosphate concentration in compartment 1 was consistent with plasma phosphate in 
all model approaches. 
 
Figure 4. The one-compartment (upper), two-compartment (middle) and three-compartment 
(bottom) model structures including the location of the parameters f1-f3.




Table 6 provides an overview of all components in the modelling approach, including 
information on how the individual component was determined.  
Com-
ponent 
Description Determination of model component 
C1  Phosphate concentration 
(mmol/l), compartment 1 
C1(t+1)  =   
M1(t)-( f1(t)+ f2(t))× ((t+1)-(t))
V1









C2 Phosphate concentration 







C2(t+1)_b =  
M2(t) + (f2(t) − f3(t))  ×  ((t+1)-(t))
V2
 
C3 Phosphate concentration 
(mmol/l), compartment 3 
 C3(t+1) = 
M3(t)+ f2(t) × ((t+1)-(t))
V3
 
M1 Mass of phosphate (mmol), 
compartment 1 
M1(t+1) = M1(t)-( f1(t)+ f2(t)) × ((t+1)-(t)) 
M2 Mass of phosphate (mmol), 
compartment 2 
Two-compartment model: 
M2(t+1) = M2(t)+ f2(t) × ((t+1)-(t)) 
Three-compartment model: 
   M2(t + 1) =  M2(t) + (f2(t) − f3(t)) ×  ((t+1)-(t)) 
M3 Mass of phosphate (mmol), 
compartment 3 
  M3(t + 1)= M3(t)+ f2(t) × ((t+1)-(t)) 
V1 Volume of distribution (l), 
compartment 1 
Estimated (a man weighing 70 kg): 3 l or 14 l 
V2 Volume of distribution (l), 
compartment 2 
Estimated (a man weighing 70 kg): 3 l, 11 l or 35 l 
V3 Volume of distribution (l), 
compartment 3 
Estimated (a man weighing 70 kg): 8 l or 35 l 
f1 Phosphate eliminated 
through dialysis clearance 
(mmol/min) 
f1(t) = kd  × (C1(t)-Cd(t)) × s 
f2 Phosphate diffused 
between compartment 1 
and 2 (mmol/min) 
f2(t) = k1 × (C1(t)-C2(t)) 
f3 Phosphate diffused 
between compartment 2 
and 3 (mmol/min) 
f3(t)= k2 × (C2(t)-C3(t)) 
kd Dialyser clearance of 
phosphate  (l/min) 
Estimated: 1, 1.4, 2, 2.5, 2.8, 3.5, 6 or 9 l/min 
k1 Mass transfer coefficient 1 
(l/min) 
Estimated: 3, 3.5, 5, 9 l/min 
k2 Mass transfer coefficient 2 
(l/min) 
Estimated: 1 or 5 l/min 
S Dialysis status (0 = no, 1= yes) 
Table 6. Overview of the model components. 
 




4.1.2. MODEL MODIFICATION AND VALIDATION 
The model simulations were modified and tested on experimental data (95), including 
plasma phosphate samples from eight HD patients undergoing 4-hour and 8-hour HD 
combined with 2-hour post-dialysis. The samples included the mean values of eight 
measures obtained during each of the two treatment regimens. 
Different steps were applied to modify and test the model simulations and to 
determine the best model approach: 
 Graphical modifications were made to modify and identify the best model 
simulations in the 4- and 8-hour treatment. This included changing the 
structure of the model (one, two or three compartments) and its components 
(V1, V2, V3, kd, k1 and k2).  
 R2 calculations of the best graphical results.  
 Calculation of mean R2 values in each pre-selected V case. 
 Direct comparison of the means from step 3 between the 4-h and 8-h 
treatments. 
 With each treatment, the best model performance was tested using the 
opposite treatment regimen (ignoring kd). This included evaluation and 
comparison of graphical results and calculation of R2 values.  
 The results of steps 4 and 5 were compared to determine if the two R2 values 
corresponded to the same model.  
4.2. RESULTS 
The one-compartment model simulations fitted poorly with the experimental data as 
they failed to show the stabilisation of plasma phosphate from the early stages of the 
treatment. In contrast, the two- and three-compartment approaches showed good 
agreement with the experimental data in both the 4-hour and 8-hour HD. This was 
seen both graphically and in high R2 values (0.878 to 0.989). Table 7 presents the most 
relevant characteristics of the two- and three-compartment model variations providing 
the best agreement with the experimental data. 
 




Table 7. The two- and three-compartment model variations providing the best agreement with 
the experimental data. Model variation numbers correspond to the ones presented in the paper. 
R2: Coefficient of determination; kd: Dialyzer clearance of phosphate; k1: Mass transfer 
coefficient 1; k2: Mass transfer coefficient 2; V1: Volume of distribution, compartment 1; V2: 
Volume of distribution, compartment 2; V3: Volume of distribution, compartment 3. 
The best performance model variations from the 4- and 8-hour treatment were seen as 
model variation no. 3 (4-h HD) and no.10 (8-h HD), respectively (see Table 7). When 
the model variations were tested on the opposite treatment (experimental data), the 
three-compartment model (no. 10) had the best graphical fit and the highest R2 value 
(0.979 versus 0.903). Model variation no. 10 corresponded to the best performing 
model, yielding the highest R2 value when the evaluation was based on the V values 
exclusively. Figure 5 illustrates the graphical results of the best performance model 













Figure 5. The graphical comparison between the best performance model variation (solid line) 
and the experimental data (filled circles) for 4-hour HD (left) and 8-hour HD (right). Time = 
0 indicates the beginning of HD. R2: Coefficient of determination; HD: Haemodialysis. 
4.3. CONCLUSIONS 
In conclusion, both two- and three-compartment model variations provided good 

























































































of plasma phosphate in HD patients. However, the three-compartment model 
performed best. Still, further validation and confirmation is necessary; particularly 
relevant would be to test the model simulations on other treatment regimens and to 
include parameters of relevance to the HD patient. It would also be relevant to test 








CHAPTER 5. STUDY II  
This chapter summarises the work conducted in the paper entitled “Phosphate kinetic 
models in hemodialysis: A systematic review” (2). The summary focuses on the 
methods, results and conclusions. 
5.1. METHODS 
The second study aimed to survey and compare intra- and inter-dialytic phosphate 
kinetic models in HD to identify their potential and limitations.  
A systematic review was performed and reported in accordance with the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (96). The 
review also conformed to current review guidelines (97,98). The review included five 
phases as outlined in Figure 6.  
 
Figure 6. The five phases of the review process. 
The preliminary phase included designing a systematic search protocol to structure 
the search and ensure reproducibility. The main elements of the protocol included 
reflections on 1) background and research question, 2) inclusion and exclusion 
criteria, 3) search strategies including selection of information sources/databases, 
search terms and search functions and 4) strategy for the selection and critical review 


















Table 8. Key elements of the search protocol. HD: Haemodialysis; HDF: Haemodiafiltration; 
HF: Haemofiltration; PD: Peritoneal dialysis. 
The preliminary phase led to the search phase. A systematic search was performed in 
the preselected databases and through the additional search channels using various 
search terms and functions (see Table 8). The Search phase was followed by the 
Review and assessment phase. Relevant records were identified through three steps: 
1) removal of duplicates, 2) title and abstract screening and 3) full paper screening. 
Step 1 – Removal of duplicates was performed in RefWorks (2010) using the functions 
Exact duplicates and Close duplicates. Step 2 - Title and abstract screening included 
an evaluation of language and relevance of subject matter. Step 3 - Full paper 
screening included a thorough scan of each remaining paper to determine its eligibility 
according to the specific field of interest and the inclusion and exclusion criteria. At 
this step, papers were excluded if the following exclusion criteria applied: 1) 
language, 2) wrong intervention/treatment, 3) publication type, 4) unrelated, 5) 
conference abstracts. The records that were not excluded following these three steps 
were included in the review.  
The next phase, the Extraction phase, included extraction of relevant data from each 
of the included studies according to the following criteria:  
 Model approach: Author, year, model summary, number of compartments, 
assumptions, included parameters and comments on strengths and 
weaknesses.  
 Validation approach - treatment setup:  Dialyzer, dialysis machine, dialysate 





Inclusion criteria: 1) records on intra-dialytic and/or inter-dialytic 
phosphate kinetic modelling within HD therapy, 2) in English, 3) 
published full-text peer-reviewed journal papers. 
Exclusion criteria: records with exclusive focus on dialytic phosphate 





Primary search channels/databases: PubMed (Medline), EMBASE, 
Scopus and Web of Science.  
Additional search databases/information channels:  
- Google.com: Used to identify the most recent material within the 
area and to stay updated throughout the process. 
- Scholar.google.com: Used to identify scientific literature including 
specific papers (references from other papers, etc.). 
- Key scan of relevant references. 
Search terms A variety of different search terms and words relevant to the problem area 
were applied. This also included synonyms, near synonyms, acronyms 
and different spellings. 
Search 
functions 
Various search functions were used to achieve the most comprehensive 
search possible: Boolean operators, thesaurus searches, combination of 
thesaurus and free-text searches, parentheses, truncation, phrase search, 
abstract, title and keyword search, advanced search, free-text searches, 
”Related articles”/”Related citations”, reference searching. 




dialyzer phosphate clearance and vascular access.  
 Validation approach - study design: Number of test subjects, gender, age, 
number of trials, sampling intervals, treatment duration, key findings and 
validation results (coefficient of determination (R2) or residual sum of 
squares (RSS)).  
In the final phase, the Synthesis and reporting phase, the extracted data were 
summarised and mapped in the following boxes/tables: 1) Summary of the included 
models, 2) parameters of the models, 3) treatment setup and 4) study design. The 
synthesis also included quality assessment of the studies. This included an assessment 
of each study against 14 quality indicators that were framed according to The 
Newcastle-Ottawa Scale (NOS)(99). The assessment against each quality indicator 
provided the individual study with a quality score of 0, 0.5 or 1 (poor, medium or 
good). The total quality score assigned each study to one of the following categories; 
low-quality study (0-4), medium-quality study (5-9) or high-quality study (10-14).  
5.2. RESULTS 
5.2.1. IDENTIFIED STUDIES 
A total of 1,964 records were identified from the review after 875 duplicates had been 
removed. Seventy-six records remained after screening of titles and abstracts, and 
eleven eligible full-text papers (1,68,88–91,93,94,100–102) were extracted for 
evaluation and included in the systematic review. However, only nine phosphate 
kinetic models were identified as three papers reported on the same model (100–102). 
Table 9 summarises some of the key findings of the eleven studies (1,68,88–
91,93,94,100–102). 
























3 6h HD  Close agreement with the 
experimental data but no 








2 4-5h HD + 
12h post-
dialysis 
Close agreement with the 
experimental data but no 







11 3h HD + 1h 
post-
dialysis 
Close agreement was 
found: R2 values between 







2 4 h HD All models show satisfying 
fits with the experimental 
data. However, one model 







4 3-5h HD + 










7 3-5h HD + 












9 4h HD + 1h 
post-
dialysis 
Close agreement with the 
experimental data. How-
ever, the validation results 







8 2h and 4h 
HD + 1h 
post -
dialysis 
Close agreement with the 
experimental data but some 
minor deviations at the end 
of HD. The validation 




See Agar et 
al. 
10 - Unvalidated 4/LQ 
Debowska 
2015 (100) 
See Agar et 
al. 
8 4h HD + 1h 
post 
Close agreement with the 
experimental data. How-
ever, the validation results 








5 4h and 8h 
HD + 2h 
post 
Fit the experimental data 
well. A three-compartment 
model shows the best fit 
(R2: 0.979 in the 4-h and 
0.951 in 8-h) 
9.5/HQ 
Table 9. Key findings of the included studies. HD: Haemodialysis; LQ: Low quality; MQ: 
Medium quality; HQ: High quality; R2: Coefficient of determination.




5.2.2. QUALITY ASSESSMENT 
Figure 7 illustrates the extent to which the included studies met the four quality 
indicator areas; Model approach, Validation and conclusions, Study design and 
Treatment setup. 
 
Figure 7. Distribution of the quality of the studies (in percentage) divided by the four quality 
indicator areas. The four areas are assessed as being met, partly met or not met. Indicators are 
listed in decreasing order from most frequently met to least frequently met. 
Figure 8 shows the extent to which the studies met each of the 14 quality indicators.  
 
Figure 8. Distribution of the quality score of the studies (in percentage) by quality indicators. 
The indicators are assessed as being met, partly met or not met. Indicators are listed in 
decreasing order from most frequently met to least frequently met.
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Direct comparison of the identified studies was complicated mainly due to variations 
in model structures and included components. Both one-, two-, three- and four-
compartment model structures were identified and 2 to 11 components were 
identified. Unclear validation results and different evaluation approaches complicated 
the comparison even further. Hence, the review did not identify a specific model with 
the best performance. However, it was cautiously concluded that three- and four-
compartment models outperform one- and two-compartment models. Moreover, some 
limitations seem to be present. For instance, it was found that some parameters with 
known influence on the phosphate kinetics were ignored in the models and could 
influence model accuracy. Another limitation was a vague determination of model 
constants and coefficients, which could have been more physiologically based. Hence, 
the results call for modifications of the current models. Reservations also apply to the 
evaluation procedures, which are insufficient, especially as far as transparency 
regarding randomisation, drop-outs and validation results are concerned. Hence, 






CHAPTER 6. STUDY III  
This chapter summarises the work conducted in the paper entitled “Evaluation of a 
phosphate kinetic model in hemodialysis therapy – assessment of temporal robustness 
of model predictions”. The summary focuses on the methods, results and conclusions. 
6.1. METHODS 
The third study aimed to modify and validate the most promising phosphate kinetic 
model from Study I (1), a three-compartment model, to a set of real patient data. The 
goal was to individualize the model and make it more compatible with physiological 
expectations. The validation approach aimed at assessing the precision and temporal 
robustness of the model predictions. This section presents the data set, the 
modification and the evaluation approaches. 
6.1.1. DATA SET 
The data set included dialysate and plasma phosphate samples from 12 HD patients. 
Intra-dialytic samples were collected from each patient during two separate HD 
sessions. Plasma phosphate and dialysate samples were collected at 30- and 60-minute 
intervals from the beginning of HD. In addition, post-dialytic plasma phosphate 
samples covering a 2-hour period were drawn from four of the patients 30 minutes 
after each dialysis session was terminated.  
 
6.1.2. MODEL MODIFICATION AND VALIDATION 
The three-compartment model from study I (1), indicated as model variation no. 8 (4-
hour HD) and 10 (8-hour HD), was implemented into Microsoft Office Excel 2013 
and modified on the basis of the samples from the 12 HD patients. Modifications were 
made to the dialyzer phosphate clearance (kd), the volumes of distribution (V1, V2, 
and V3), the mass transfer coefficients (k1 and k2) and phosphate eliminated through 
dialysis clearance at time t (f1). The dialyzer clearance was assumed to be equal to the 
individual mean dialyzer clearance calculated from the following equation: 
 
kd   =  
(Σ phosphate conc. in dialysate )
nd
 * mean dialysate flow rate 




The component nd is the number of individual dialysate samples, and np is the number 
of individual plasma samples. The volumes of distribution in the three compartments 
were calculated according to the following three equations:




V1 = TBW * 1/3 * 1/4 
V2= TBW*1/3 * 3/4 
 V3 = TBW * 2/3  
Where TBW is total body water calculated from the formulas of P.E. Watson (103). 
The samples from dialysis number one (HD1) were used to identify the optimum k1 
and k2 values in each patient. This included determining the lowest RMSE value using 
the Solver function in Excel. 
The R2 value was determined for the model version with the lowest RMSE value in 
each individual patient when considering HD1 simulations. Subsequently, the plasma 
phosphate samples from dialysis number two (HD2) were used to validate the best 
performance model from HD1 in each patient. The validation on the HD2 values 
included determination of the R2 value in each individual patient without changing 
the model components. Model components were retained to assess the temporal 
robustness of model predictions. 
6.2. RESULTS 
Table 10 presents the determined model components (V1, V2, V3, kd, k1 and k2) for 
































































































































Table 10. Model components for each of the 12 patients and the corresponding R2 values for 
HD1 and HD2, respectively. The (*) indicates patients who underwent both intra- and post-
dialytic sampling. The (**) indicates statistically significant (|z obs. value| > 1.96) difference 
between R2 values. R2: Coefficient of determination; kd: Dialyzer clearance of phosphate; k1: 
Mass transfer coefficient 1; k2: Mass transfer coefficient 2; V1: Volume of distribution, 




compartment 1; V2: Volume of distribution, compartment 2; V3: Volume of distribution, 
compartment 3. 
Figure 9 gives the graphical results of the best performance models (R2 values) 
evaluated from HD1 simulations. The median R2 values were 0.985 and 0.992 for 
HD1 and HD2, respectively, when fitted to intradialytic samples only. Median R2 
values were 0.882 and 0.963 for HD1 and HD2, respectively, when fitted to both intra- 

















In conclusion, the model seems promising regarding simulation of individual plasma 
phosphate concentrations, especially when considering intra-dialytic phosphate 
kinetics. Furthermore, the positive results from the HD2 simulations indicate the 
  
  
Figure 9. The best performance models on the basis of HD1 R2 values for intra-dialytic 
values only (A: patient no. 6) and for both intra-dialytic and post-dialytic values (B: 
patient no. 8), respectively. The model simulations for HD1 are illustrated on the left, 
and the model simulations for HD2 are illustrated on the right. The time for termination 




















































































































temporal robustness of the model predictions. However, even though promising, the 
model requires further validation on a larger sample, preferably with post-dialytic 
values to verify the current results and to see if more significant results could be 
obtained. Moreover, other components potentially influencing the plasma phosphate 




CHAPTER 7. STUDY IV  
This chapter summarises the work conducted in the paper entitled “Implementation 
of a coagulation component into a phosphate kinetic model in hemodialysis therapy – 
a potentially useful tool for quantitative detection of clotting problems”. The summary 
focuses on the methods, results and conclusions. 
7.1. METHODS 
Study IV aimed at adding a coagulation component to the version of the three-
compartment model presented in Study III. This section presents the modification and 
validation approaches.  
7.1.1. MODEL MODIFICATION AND VALIDATION 
In this study, the three-compartment model was modified and validated on the intra-
dialytic dialysate and plasma phosphate samples from the data set (n=12x2) presented 
in Study III. Modifications were made to the model components f1, k1 and k2 on HD1 
and HD2 samples without changing the other components of the model. The 
modifications included adding a linear slope as a clearance reduction (/h) to the model 
to simulate intra-dialytic coagulation of the circuit and dialyzer. This was based on 
the hypothesis that the dialyzer clearance of phosphate might gradually decrease 
during treatment due to clotting of the extracorporeal system and dialyzer. Intra-
dialytic coagulation is a well-known and unavoidable phenomenon in HD therapy 
despite anticoagulants. It is known to have a negative effect on treatment 
effectiveness, for instance, on the dialytic removal of phosphate (72,73,104). The 
hypothesis that plasma phosphate would decrease following an intra-dialytic linear 
clearance reduction per hour was an assumption made in this study unsupported by 
previous studies. 
The following two equations are the original (Study I and III) (1) and the modified 
equations, respectively, for the component phosphate eliminated through dialysis 
clearance at time t ( f1):  
 f1(t) = kd  × (C1(t)-Cd(t)) × s                                            (original) 
 f1(t) = kd  × (C1(t)-Cd(t)) × (1-(SLc×((t-t0)-Dd /2))) × s       (modified) 
In the equations, s indicates dialysis status (0 = no, 1= yes), C1(t) is the phosphate 
concentration in plasma (at time t), Cd(t) is the dialysate phosphate concentration (at 
time t), t0 is the time for beginning of dialysis, kd is the mean dialyzer clearance, Dd is  
dialysis duration and SLc is the slope of the clearance reduction (/h). 




First the Excel Solver function was used to identify the two mass transfer coefficients 
(k1 and k2), i.e. the model simulation with the lowest RMSE value, in each of the 24 
treatment cases for a model without clearance reduction. Second, the Excel Solver 
function was used to identify the clearance reduction (SLc) and the two mass transfer 
coefficients (k1 and k2) in each of the 24 treatment cases for a model with clearance 
reduction. The corresponding R2 values were calculated. 
In addition, the best performance model simulations (with slope) for HD1 and HD2 
for each patient were compared with the best performance model without slope for 
the corresponding treatment.  
7.2. RESULTS 
Table 11 presents the identified clearance reduction (linear slope) and the 
corresponding four R2 values for each of the 12 patients with two treatment cases 
each. The four R2 values for each patient represent the agreement between measured 
and modelled plasma phosphate for the following evaluations; HD1 with and without 
the slope, and HD2 with and without the slope.  
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Table 11. Identified slope and the corresponding R2 values (HD1 with and without slope plus 
HD2 with and without slope) for each of the 12 patients. The (*) is patients who underwent both 
intra- and post-dialytic sampling. The (**) indicates statistically significant (|z obs. value| > 
1.96) difference between the R2 values (without and with slope) for the specific treatment. 
Figure 10 gives an example of the graphical results for a typical treatment, patient no. 
5 HD1, i.e. the treatment with the ninth largest relative improvement in RMSE 
(median relative improvement).







Figure 10. The four graphic results of the best performance model evaluated from HD1 R2 
values (Patient no. 1, R2=0.992). A is the results from HD1 without (left) and with (right) 


























































Figure 10. The graphical comparison between the model (solid 
line) and experimental data (filled circles) for a typical treatment 
(patient no. 5 HD1) without and with a linear slope.  
 




It can cautiously be concluded that a linear clearance reduction is promising in 
phosphate kinetic modelling. The linear clearance reduction may be explained by 
intra-dialytic coagulation. However, making any final conclusions about the 
completeness, usefulness and validity of the model is not possible until further testing 
of the model has been accomplished. Future studies could benefit from more patients 
and more samples in each patient case. Such studies should address potential risk 
factors for intra-dialytic clotting of the extracorporeal system and dialyzer. Further 
development of the model may produce a useful tool with a potential for quantitative 





CHAPTER 8. DISCUSSION 
This chapter is divided into five subsections: 1) Summary of the main findings, 2) 
Interpretation of the main findings and modelling approaches, 3) Methodological 
considerations, 4) Conclusions and 5) Future perspectives. 
8.1. SUMMARY OF MAIN FINDINGS 
This PhD study on hyperphosphataemia management in HD therapy presents some 
new approaches within the field of phosphate kinetic modelling in HD therapy. Four 
studies were conducted.  
Study I involved developing and evaluating new phosphate kinetic modelling 
approaches based on distribution volume assessment. One-, two- and three-
compartment structures were tested on experimental data from eight HD patients at 4 
and 8 hours of HD and 2 hours after dialysis. The two- and three-compartment 
approaches showed good agreement with the experimental data (average plasma 
phosphate samples). A three-compartment approach had the best fit. The identified 
model components and coefficients for the three-compartment model were: V1=3 l, 
V2=11 l, V3=35 l, k1=5 l/min and k2=1 l/min. The most suitable dialyzer phosphate 
clearance (kd) differed between the 4-hour and 8-hour treatments (3.5 l/min versus 1.4 
l/min).  
Study II, a systematic review of existing phosphate-kinetic models in HD therapy, 
identified 11 relevant studies examining nine different models. The papers were 
thoroughly reviewed, compared and assessed. It was not possible to single out any 
particular best-performing model due, among others, to lack of validation results.   
In Study III, the best performance model from Study I, a three-compartment model, 
was tested on individual patient data (n=12) including dialysate and plasma phosphate 
samples from two separate treatments from each patient. The model was modified 
with the aim of individualising the model and making it more compatible with 
physiological expectations. When fitting the model to individual plasma phosphate 
samples, we found a rather good agreement with the model simulations in most patient 
cases, especially for intra-dialytic values, indicating a high empirical validity. 
Temporal robustness was found when the model from HD1 was tested on HD2 
samples; eight of the 12 patients demonstrated higher R2 values for HD2 than for HD1 
– this included three patients with both intra- and post-dialytic samples. The median 
(interquartile range) model coefficients and components were: V1=3.53 (2.82-3.69) l; 
V2=10.57 (8.46-11.07) l; V3=28.17 (22.56-29.51) l; kd=8.94 (7.90-9.45) l/h, k1=17.06 
(13.82-31.73) l/h; k2=12.43 (7.15-23.05) l/h.  
The model in Study IV presented a build-on to the model presented in Study III. The 
modifications included adding a linear clearance reduction (/h) as an assumed 
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coagulation component to the model. The model with the coagulation component was 
validated on the patient data presented in Study III (24 treatments). Seventeen of the 
24 model simulations improved when the linear clearance reduction was added to the 
model. However, only three of the 17 improvements in R2 values were found to be 
statistically significant (|observed z value|>1.96). The identified (median) components 
and coefficients for the model in Study IV were (n=24): slope=0.125/h; V1=3.53 l; 
V2=10.57 l; V3=28.17 l; kd=8.88 l/h, k1=44.89 l/h; and k2=8.76 l/h. We found a 
correlation between the slopes for HD1 and HD2 for a given patient. No correlation 
was found between the slopes and the corresponding 3-hour-point plasma phosphate 
concentrations. 
8.2. INTERPRETATION OF THE MAIN FINDINGS AND 
MODELLING APPROACHES  
8.2.1. MODEL COMPONENTS AND COEFFICIENTS 
The difference in kd values in Study I (1) between the 4- and 8-hour model simulations 
(3.5 l/min versus 1.4 l/min) for the most promising model, the three-compartment 
model, was expected due to different diffusive rates considering the duration of 
dialysis (66). The identified volumes of distribution values (V1=3 l, V2=11 l and 
V3=35 l,) were to some extent compatible with physiological expectations. The total 
volume of distribution of phosphate (49 l) would be consistent with the TBW in an 
average person weighing approximately 70 kg (103) and it would be consistent with 
the speculation that phosphate has a large distribution volume (69). Furthermore, the 
distribution volumes in compartment 1 (V1=3 l) and 2 (V2=11 l) approximately 
correspond to the fluid in the plasma and in the interstitial space, respectively (105). 
However, a limitation of the distribution volume assessment approach in Study I is 
that components such as gender, age, weight and height were not considered, even 
though they are known to influence the TBW (103). The k1 and k2 values (k1=5 l/min 
and k2=1 l/min) were evaluated as likely, considering biological processes, though 
difficult to assess. The kd values were questionable, however, as they were extremely 
high and thus unlikely considering current treatment regimens (66).  
The components and coefficients of the model presented in Study I (1) were adjusted 
in Study III (and Study IV) on the basis of model modification on individual patient 
data. These adjustments enabled individualisation of the model and thus produced a 
higher theoretical validity; the volumes of distribution (median : V1=3.53 l; V2=10.57 
l; V3=28.17 l) were identified using acknowledged formulas (103) that took into 
account gender, age, weight and height, and the dialyzer phosphate clearance (median: 
kd=8.94 l/h) was calculated from phosphate samples (plasma and dialysate) and 
observed dialysate rates in the specific patient case. However, the approach of 
determining the mass transfer coefficients (median: k1=17.06 l/h; k2=12.43 l/h) using 
the Solver function in Excel generated some rather extreme and thus physiologically 




unlikely values in a few treatment cases. This problem was especially pronounced in 
a couple of the treatment cases with both intra- and post-dialytic samples – a result 
that might indicate that further model modifications are required for this particular 
type of data. The problem with extreme k1 and k2 values was also observed in some 
of the treatment cases in Study IV. 
The assumption about constant compartment volumes not accounting for individual 
fluid removal during HD is a questionable element of the model approaches in Study 
I, III and IV. Hence, ultrafiltration is known to affect the dialysis clearance of 
phosphate (64,81). Another questionable assumption in Study I and III is that dialysis 
removal and diffusion between compartments were considered the only effects 
causing changes in plasma phosphate. This implies that we did not take into 
consideration different variations in the treatment such as dialysate rate, dialyzer type 
and blood flow rate – factors that could all potentially influence the phosphate level. 
The model approach also ignores other influencing factors such as hormonal 
influence, intra-dialytic clotting of the extracorporeal system and dialyzer, calcium 
concentration, pH level, phosphate-binding agents, intestinal absorption and skeletal 
turnover (64,72,73,86,104). Ignoring these potential influencing factors is also a 
problem in Study IV. However, in this study, a coagulation component was added as 
a linear clearance reduction to the model in an attempt to simulate the intra-dialytic 
clotting of the extracorporeal system and dialyzer. The linear clearance reduction led 
to improvements (R2) in 17 of 24 model simulations, indicating that the input of a 
linear clearance reduction could be a valid component in intradialytic phosphate 
kinetic modelling in HD therapy. However, only three of the 17 improved R2 results 
obtained after adding the clearance reduction to the model were considered 
statistically significant - a result that might be caused by the relatively limited number 
of samples in each treatment. Hence, more frequent sampling should be considered in 
future studies. In the study, it was concluded that the effect of the linear clearance 
reduction may be explained, at least partly, by the intradialytic coagulation. However, 
this conclusion was made on a rather uncertain basis and further validation is required 
before definitive conclusions can be made. Even so, the input of the clearance 
reduction seems to improve the model and is considered a promising modelling 
approach. 
Ignoring potentially influencing treatment-specific and patient-specific factors on 
plasma phosphate concentration is a general problem within phosphate kinetics 
modelling. This is evident from the systematic review (2). In the review, it was found 
that existing models include between two and eleven model components with known 
influence on the phosphate balance. However, none of the models were found to 
consider all potentially influencing factors – a perspective that could affect the 
accuracy of the models in some patient cases. Moreover, ignoring these factors 
questions the theoretical validity of existing models and limits their practical potential.




8.2.2. MODIFICATION AND VALIDATION APPROACHES  
The modification and validation approach in Study I is advantageous to some extent. 
One advantage is that the model is modified and tested on two different treatment 
regimens; 4- and 8-hour HD (95). The promising results of both 4-hour HD and 8-
hour HD increase the prospect that the model will be used as it may be useful in both 
CHD and NHD patients (13). Another advantage is the additional modification and 
validation on 2-hour post-dialytic phosphate concentrations (95). In comparison to the 
normal 1-hour post-dialytic approach, the 2-hour post-dialytic modifications and 
testing is improvement on the approaches in previous studies (2). Although the 
modification and validation approach is advantageous in these respects, some 
important limitations should be acknowledged concerning the modification and 
validation approach in Study I.  One important issue is that the model simulations are 
modified and tested on experimental data (95) that include mean plasma phosphate 
values exclusively. This could produce incorrect results in some individual patients. 
For instance, the total distribution volume is known to differ according to gender, age, 
weight and height (103). Another issue is the sample size; the modifications and 
testing on mean values based on patient values from only eight HD patients 
necessarily means that our results should be confirmed in a larger population. 
Some of the modification and validation problems in Study I (1) are addressed in 
Study III (and IV). One important improvement in Study III (and IV) in comparison 
to Study I is the modifications and validation on individual patient data. The 
individualised approach is highly relevant as patient- and treatment-specific factors 
are known to influence the plasma phosphate concentration (64,72,73,86,104). Thus, 
in Study III (and IV), the component kd was determined on the basis of patient-specific 
treatment values (dialysate flow rate) and collected dialysate and blood samples. This 
produced values more in line with expected clearance values reported in previous 
studies (68,85,106). In comparison, the dialyzer clearance component was determined 
by system model simulations (Excel) in Study I. In addition to improvements of the 
dialyzer clearance component, individualisation of the volumes of distribution 
components (V1, V2 and V3) was also incorporated into the model (Study III and IV). 
Hence, the components included individualised calculations of TBW by taking into 
account the individual patient’s weight, age, gender and height. Overall, these changes 
have heightened the theoretical validity of the model compared to the model presented 
in Study I (16). Another improvement in Study III (and IV) in comparison to Study I 
is the larger sample size of 12 HD patients; even so, the sample size is still considered 
relatively small, especially the proportion of patients (4 of 12 patients) with post-
dialytic values. Despite the relatively small sample size, the validation of the model 
on two sets of individual patient data in each patient case (HD1 and HD2) strengthens 
the credibility of the validation results. Furthermore, as illustrated in Study III, this 
approach enables assessment of the temporal robustness of the model predictions. In 
this regard, a rather high agreement was found when comparing the model simulations 
to HD2 samples, even though the model was only modified to HD1 samples. This is 
assessed to indicate the temporal robustness of the model. However, it is expected that 




treatment-specific factors will deviate, for instance dialyzer phosphate clearance, 
especially if the model is validated on treatments separated by longer intervals than in 
the present study. The validation on data sets from two separate treatments to test for 
temporal robustness of model predictions has not been performed in previous studies 
and thus constitutes an untested validation approach within phosphate kinetics 
modelling (2).  
From the results of the systematic review (2), it is evident that eight models 
(1,68,88,90,91,94,100,101), including the model presented in Study I (1), are 
promising in terms of accuracy, i.e. they provide high agreement with experimental 
data (2). However, the validation approaches seem to be encumbered with different 
challenges that question their validity. The main problems are that validation is based 
on small datasets, which could compromise generalisability; and lack of clear 
validation results (2), which compromises the quality and accuracy of the models. 
Moreover, consistency regarding study designs and treatment setups is lacking, and 
evaluation of dropouts and randomisation is not sufficiently described (2).  
8.2.3. MODEL STRUCTURE AND COMPLEXITY 
One of the main results in Study I (1) was the need for more than one compartment to 
simulate the measured plasma phosphate. This result confirms the results of other 
model studies examined in the systematic review (2). The studies in the systematic 
review include between two and four compartments (68,89–91,93,94) or demonstrate 
a one-compartment model structure with an influx from an unknown compartment 
(88,100–102) – an approach that can be interpreted as identical to a two-compartment 
model. The result that a simple one-compartment model is considered insufficient to 
describe intra- and post-dialytic phosphate kinetics was expected since the plasma 
phosphate is known to stabilise from early in the treatment, indicating an influx of 
phosphate from another compartment (107–109). The stabilisation of phosphate is 
evident from the validation results in Study I, III and IV.  
In Study I, we found a good agreement with the experimental data with both the two- 
and the three-compartment model approaches, even if the best performance model had 
a three-compartment structure. This result is in accordance with three (68,93,94) of 
the studies identified from the review which found it difficult to describe the 
phosphate stabilisation using a two-compartment approach. The model by Spalding et 
al. (68) even found it difficult to describe the dialytic phosphate kinetics using a three-
compartment model in some patient cases. This result might testify to the need for 
individualising the model structure in future modelling. The need for a multi-
compartment model to simulate phosphate kinetics confirms the complexity of 
phosphate kinetics (54,81).  
In Study III and IV, the three compartments are set to be consistent with plasma 
(compartment 1), the interstitial space (compartment 2) and the intra-cellular space 




(compartment 3). This approach is similar to the common assumption in the two-
compartment approaches that one compartment is equal to the extracellular space and 
another is equal to the intracellular space (2). This approach, however, does not allow 
for the possibility of other distribution volumes. The model approach presented in 
Study I (1) deviates slightly in this respect because it is based on distribution volume 
assessment and therefore includes specific suggestions, in litres, for distribution 
volumes for the included compartments. However, the identified volumes of 
distribution (V1=3 l, V2=11 l and V3=35 l) of the best performance model in Study I 
take approximately the same form as expected for plasma, the interstitial space and 
intra-cellular space and thereby follow the pattern of other studies. The volumes of 
distribution (V1=3 l, V2=3 l and V3=8 l) of the second best performance, the three-
compartment model in Study I (see Table 7), indicate that phosphate is only 
distributed in the extracellular space. This result would not be consistent with the 
current speculation that phosphate is a small molecule with a large distribution volume 
(69).  
Although the results indicate the need for a minimum of two compartments, in the end 
the choice of the number of compartments would often depend on the ability of the 
individual model to simulate the experimental data. Hence, a one-compartment 
simulation like the models proposed by Sugisaki et al. (88) and Agar et al. (101) with 
an in-flow of phosphate from an unidentified depository could prove just as useful as 
a multi-compartment model like the one proposed by Spalding et al. (68) if it more 
accurately fits the experimental data (68). In the end, the usefulness of the model will 
sometimes depend on the strength of its empirical validity albeit this could 
compromise its theoretical validity (16). It is considered that a model with high 
empirical validity could be a useful tool in the prediction of plasma phosphate kinetics 
and phosphate removal even though the theoretical validity was compromised. 
However, if the theoretical validity is compromised, this would limit the usefulness 
of the model if it is to be used to increase our understanding of biological processes 
and treatment effects. Overall, the usefulness of the model will be determined by its 
intended purpose (16). 
8.2.4. MODEL POTENTIAL  
Study I (1) provides a novel, yet immature model approach with distribution volume 
assessment as a seemingly new feature within the modelling field. Despite some 
questionable assumptions and coefficients, the model could have the potential to 
predict plasma phosphate values and be applied in practice. This is stated on the basis 
of the high empirical validity considering both 4- and 8-hour (plus 2-hour post-
dialysis) model simulations. In this regard, however, it should be considered that the 
model has been modified and tested on experimental data (95) that include mean 
plasma phosphate values exclusively. This could produce incorrect results in some 
individual patients, since different treatment- and patient-specific factors could 
influence the phosphate concentration (64,73,86). The approach of distribution 
volume assessment to determine distribution volumes in phosphate kinetics modelling 




could, however, be a rather interesting method in future model studies. The feasibility 
of this approach should, however, be evaluated in individual experimental data. 
The promising results of Study III indicate that the three-compartment model could 
serve as a tool for prediction of individual plasma phosphate kinetics. It also has the 
potential for quantifying dialytic phosphate removal based on prediction from the 
treatment-specific pre-dialytic phosphate sample. However, even though improved 
and less descriptive, the model still has some questionable features. For instance, the 
mass transfer coefficients (k1 and k2) are questionable in a few cases and the model 
continues to ignore other potentially relevant factors that influence the plasma 
phosphate level (64,73,86). Hence, these issues question the theoretical validity of the 
model and it may therefore benefit from further modifications in future studies.  
When considering the promising results from the model validations in Study IV, it 
seems that a linear clearance reduction could be beneficial in intra-dialytic phosphate 
kinetic modelling in HD therapy. However, of the 17 treatments favouring a linear 
clearance reduction, only three showed statistically significant improvements. Further 
validation should thus be made to make any final conclusions about the model input 
of a linear clearance reduction. Intra-dialytic coagulation is considered to be a 
reasonable or at least partial explanation for the clearance reduction in the model. 
Hence, intra-dialytic coagulation of the extracorporeal system and dialyzer is an 
unavoidably phenomenon in HD therapy and is known to have a negative effect on 
phosphate removal (72,73). Adding a linear clearance reduction to the model is a 
novel approach within the field of phosphate kinetics modelling and could perhaps be 
beneficial in future modelling. For instance, it is suggested that it could be applied as 
a tool for quantitative detection of individual clotting problems. 
Other models with practical potential include the models by Agar et al. (101) and 
Spalding et al. (68). These models were found to be high-quality models (2) that 
showed promising validation results. However, no clear validation results were 
provided to verify the promising results. Still, it appears that the experimental stage 
of the model by Agar et al. (101) is most advanced. Another potentially useful model 
is that by Maasrani et al. (94). This model has the largest number of model 
components (n=11) and shows good agreement with experimental data. However, the 
validation results of this model are questionable as the model has been tested only in 
four paediatric patients. Overall, it is difficult to conclude which model performance 
is best based on existing validation results. A direct comparison of the models and 
their performance is also hampered by differences in treatment setups and sampling 
methods. For example, using blood flow rate and dialysate flow rate together with 
dialyzer membrane and surface area may affect phosphate clearance (72). It should 
also be considered that some models may be limited to specific treatment modalities. 
Hence, it is recognized that short 2-h HD (SHD), NHD and CHD differ in terms of 
solute removal, time and blood flow rates (66,71,110,111). Only the model variations 
presented in this thesis and the model by Agar et al. (101) have been tested in different 
treatment regimens. Moreover, it should be stated that the models by Ruggeri et al.




 (91)  and Sugisaki et al. (88) do not simulate post-dialytic phosphate kinetics – a 
perspective that limits their use. 
Finally, when appraising the potential of a model, its complexity also has to be 
considered. On the one hand, a simple approach such as the model by Agar et al. (101) 
would be relevant because of its practical potential. On the other hand, a more 
sophisticated model like that proposed by Spalding et al. (68) may increase our 
understanding of the biological processes (16,17). In the end, which model is the better 
would depend, as already stated, on the field of application. 
8.3. METHODOLOGICAL CONSIDERATIONS  
8.3.1. STUDY I 
The modification and validation based on mean experimental values and the ensuing 
lack of individualisation of model components and coefficients is a major weakness 
of this study. This is especially evident from the high kd values, which are not likely 
considering current treatment regimens (66). Ignoring of age, gender, height and 
weight in the calculation of the volumes of distribution is another important issue. 
These shortcomings question the theoretical validity and thus the potential of the 
model. Another issue is the small sample size (n=8).  
Leaving aside the major methodological issues, the modification and validation 
approach is advantageous to some extent as the model is modified and tested on two 
treatment regimens (4- and 8-hour HD) and on a 2-hour post-dialysis basis. 
Furthermore, it is evident that some of the two- and three-compartment model 
simulations show high empirical validity. Hence, although it is at a preliminary stage, 
the model approach must be considered promising and it does provide indications of 
the best model simulation. However, further validation and confirmation in larger 
datasets with individual data is required. 
8.3.2. STUDY II  
The review thoroughly evaluated and compared existing phosphate kinetic models 
and related validation approaches. Moreover, it followed acknowledged guidelines 
within the field of systematic reviewing (91–93). However, some of the 
methodological approaches need to be considered, for example the assessment 
approach, i.e. the evaluation of the model studies against the 14 quality indicators. 
Firstly, these indicators comply only with a modified version of the acknowledged 
guidelines, the NOS scoring system (99). This could question the validity of the 
assessment scale. However, as no other specific assessment tool is currently available, 
using the modified version of the NOS score was considered the most appropriate 
alternative. Secondly, the use of the 14 quality indicators risks making the assessment 
too subjective. All authors were involved in the Review and assessment phase to 
reduce the risk of subjectivity. Thirdly, we cannot ignore the possibility of 
inconsistency between what was reported in the individual study and what was 




actually done. Such discrepancies could result in an underestimation or overestimation 
of the quality of the study reviewed. Yet, the applied assessment approach is 
considered valid as the reader have to base any assessment on the study report alone. 
The search for relevant literature included a comprehensive search in four databases 
and additional hand searches, for instance, scans of key reference lists, in order to 
ensure that the search was exhaustive. However, we assume that all relevant literature 
may not have been included in the review as the inclusion and exclusion criteria 
stipulated that the review was limited to full-text papers in English. Another 
methodological consideration is the exclusive focus on phosphate modelling in HD 
therapy. This focus implies that the review does not consider potential HDF models. 
These models could have been included in the review. However, this would have 
complicated comparison of the models as the phosphate kinetics during HD and HDF 
differ (67,112).  
8.3.3. STUDY III 
An important advantage of this study is that individual experimental data were used 
to modify and validate the model. Furthermore, the volumes of distribution (V1, V2 
and V3) and the dialyzer phosphate clearance (kd) were adjusted on the basis of values 
from the individual patient. These modifications heighten the individualisation of the 
model and its theoretical validity. However, it is evident that a few mass transfer 
coefficients (k1 and k2) are rather extreme, and thus unlikely, especially when looking 
at the treatment cases with both intra- and post-dialytic samples. Hence, the model 
might benefit from further model modifications for this particular type of data.  
The validation on two data sets (HD1 and HD2) in each patient case is another strength 
of this study. In this context, the promising model simulations obtained from the 
validation on HD2 values indicate the temporal robustness of the model. However, in 
this regard, it should be stated that the promising HD2 model simulations could be a 
result of the relatively closely spaced sampling interval - HD1 and HD2 samples were 
collected only a week apart. Moreover, the consideration of 2-hour individual post-
dialysis kinetics separate the model study from previous studies as the typical 
approach has been to consider 1-hour post-dialysis kinetics (2).  
Although promising model results were obtained, it should be mentioned that the 
results are limited to a relative small sample (n=12). Hence, further validation and 
confirmation in larger datasets are required especially to evaluate the post-dialytic 
model simulations since only four patients agreed to stay for post-dialytic sampling. 
However, although the results rely on a small dataset, we consider the model 
promising, especially in the simulation of individual intra-dialytic plasma phosphate 
levels. It should also be noted that the sample size is comparable to that of many other 
model studies (2).




8.3.4. STUDY IV 
The modelling and validation approaches are relatively similar in Study III and IV. 
Hence, some of the methodology elements from Study III (section 8.3.3.) recur in 
Study IV. The experimental data are derived from the same treatments (although only 
intra-dialytic values are used in Study IV), and the V1, V2, V3 and kd values are 
calculated in the same way in the two studies (and thus identical for the eight patients 
with only intra-dialytic data). In Study III, the k1 and k2 values were determined using 
the Solver function in Excel which led to a couple of rather extreme values. Like in 
Study III, Study IV also produced some rather unlikely k1 and k2 values in some of 
the treatment cases. These relatively extreme k1 and k2 values may be related to the 
relatively high number of variables estimated in the model (one slope and two mass 
transfer coefficients) relative to the number of data points in a given treatment leading 
to an overfit of model simulations to unexplained data variations.  
Adding the linear clearance reduction as a linear slope seems to improve the model as 
17 of the 24 model simulations showed a better fit. This approach has not been tested 
prior to this study and could be a promising feature in phosphate kinetic modelling in 
HD therapy. However, the few statistically significant results (three of the 17 R2 
values) call for further evaluation. Future studies can perhaps benefit from more 
frequent sampling.  
As stated in the paper, intra-dialytic coagulation could likely explain, at least partly, 
the linear clearance reduction. However, the so-called ‘mobilization’ could also be 
explained by other factors. For instance, it has been proposed that an intrinsic 
phosphate target concentration could trigger an inflow of phosphate from an unknown 
compartment (68,88,90). However, the result that no correlation was found between 
the slopes (n=24) and the corresponding plasma phosphate concentrations at the 3-
hour time point speaks against this argumentation. To make any final conclusions 
about the reason for the promising results when adding the clearance reduction to the 
model is, however, not possible on the basis of the results of Study IV - further studies 
in a more controlled setup would therefore be necessary to evaluate the assumption of 
an intra-dialytic coagulation component.  
8.4. CONCLUSIONS 
In conclusion, this PhD thesis presents novel perspectives and ideas that may inform 
the work to devise clinically useful solutions to improve hyperphosphataemia 
management in HD therapy. Regarding the overall research hypothesis of the thesis, 
it may be concluded that a three-compartment model can simulate phosphate kinetics 
in haemodialysis with a strong correlation between simulations and patient specific 
data. 
From the systematic review, it can be concluded that no phosphate kinetic model 
seems to be ready to be implemented, even though some models have shown 
promising results. Lack of clear validation results, ignorance of factors that may 
influence plasma phosphate and questionable physiological assumptions are some of
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 the challenges complicating the use of existing models. Moreover, differences 
between evaluation procedures hamper direct comparisons between models – a 
perspective that prevents us from determining which model performs best. However, 
it can be cautiously concluded that one- and two-compartment model simulations do 
not sufficiently simulate phosphate kinetics.  
The three-compartment model (Study I, III and IV) is considered promising, 
especially the versions presented in Study III and IV. These model approaches showed 
promising results when fitted to individual patient data and demonstrated temporal 
robustness. Hence, these model approaches seem to have the potential to simulate 
individual intra- and post-dialytic (2 hours) phosphate kinetics and could potentially 
work as a quantification tool to determine treatment-specific dialytic phosphate 
removal if the pre-dialytic phosphate concentration is provided. Furthermore, adding 
a linear clearance reduction seems to be a promising feature and to be a relevant 
approach in future modelling studies. However, it remains speculative whether the 
clearance reduction could be explained, or partly explained, by intra-dialytic 
coagulation in the extracorporeal system and dialyzer. The overall conclusion is, 
therefore, to recommend further refinement and validation of the model in a larger 
sample before considering it for practical use. Moreover, it could be of relevance to 
consider other factors that potentially influence the phosphate concentration to 
increase the theoretical validity of the model.  
8.5. FUTURE PERSPECTIVES 
As stated in the Conclusion, further refinements and validation are needed before the 
three-compartment model can be considered for practical use. First of all, it would be 
relevant to test the model on a larger dataset including both intra- and post-dialytic 
samples from individual HD patients. Such a study could provide more reliable and 
thus more useful validation results. It would also be expedient to include into the 
model other relevant model components potentially affecting plasma phosphate levels 
in individuals.  
The suggestion to add a linear clearance reduction to the model should also be further 
investigated. First, it would be relevant to test its potential in a larger sample. Second, 
if possible, it would be relevant to investigate further if the linear clearance reduction 
can really be explained by intra-dialytic clotting or if another explanation could be 
found.  
Furthermore, it would relevant to test the model simulations from Study III and IV on 
prolonged HD. Hence, promising validation results for 8-hour HD have already been 
demonstrated in Study I. 
Finally, it should be stated that future research should be conducted to further explore 
the phosphate kinetics models in general. For instance, in future research, it would be 
relevant to investigate all phosphate kinetic models in identical research settings but 
with different treatment modalities. Such a comparable research set-up could help 
determine if a particular model would be more suitable in a certain setting than in 
others. Furthermore, such comparable research could help identify the best model
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performance. An updated literature search should be performed on beforehand to 
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